tbuckley/cabot-search huggingface dataset:
Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatment
Authors: Wellington Candido, Annemarie Cecile Eggen, Mathilde Jalving, Ingeborg Bosma, Reinate D Horinga, Kelly C van Heuvelen, T Jeroen N Hiltermann, Sjoukje Oosting, Emoke Racz, Melanie M van der Klauw, Anna K L Reyners, Janine Nuver
Journal: Journal for ImmunoTherapy of Cancer (2025)

Increasing numbers of patients diagnosed with advanced cancer survive long-term after treatment with immune checkpoint inhibitors (ICIs). To design adequate interventions for these survivors, knowledge regarding quality of life (QOL) and its association with long-term and late effects of ICI treatment is required. Therefore, this study aimed to evaluate QOL, neurocognitive function, psychological issues, sexuality, and comorbidities in patients surviving at least 2 years after commencing ICI treatment. We performed a cross-sectional study in patients with stage III-IV melanoma, non-small cell lung cancer (NSCLC), urothelial cell carcinoma (UCC), or renal cell carcinoma (RCC) who survived at least 2 years after the start of ICIs. We assessed QOL, neurocognitive function, psychological issues, sexual function and comorbidity in survivors. Additionally, we evaluated QOL of informal caregivers. 132 survivors (70 melanoma, 50 NSCLC, 12 UCC or RCC) and 80 caregivers were included. Median age was 65 years (range 30-85) and 50 survivors were women (38%). Median time since start and cessation of ICI treatment was 33 (range 21-91) and 18 (range 0-68) months, respectively. Average survivor QOL was comparable to the reference population, but 37 (28%) survivors had poor QOL. Depression and anxiety were negatively correlated with all QOL domains. Although immune-related adverse events were common, there was no association with lower QOL. Caregiver and survivor QOL were only weakly related. Neurocognitive concerns and formally tested neurocognitive impairment were present in 22 (17%) and 13 (15%) survivors, respectively, and were not associated with a diagnosis of brain metastases. Men had a high prevalence of erectile dysfunction and low sexual satisfaction. Half of the survivors met the criteria for the metabolic syndrome. At least 2 years after the start of ICI treatment, one-quarter of cancer survivors had a clinically relevant lower QOL. This was associated with symptoms of depression and anxiety, but not with immune-related adverse events. Sexual issues and metabolic syndrome are prevalent. Survivorship care should address these issues in this population.
SITC strategic vision: prevention, premalignant immunity, host and environmental factors
Authors: Sasha E Stanton, Kristin G Anderson, Tullia C Bruno, Christian M Capitini, Mary L Disis, Jennifer McQuade, Laszlo Radvanyi, Claire Vanpouille-Box, Jennifer Wargo, Kelly J Baines, Megan M Y Hong, Adnan Rajeh, Raymond H Kim, Phillip Awadalla, Lauren K Hughes, Saman Maleki Vareki
Journal: Journal for ImmunoTherapy of Cancer (2025)

Cancer immunotherapy has improved the survival of a subset of patients by harnessing the power of the immune system to find and destroy malignant cells. The immune system also protects the host by destroying developing premalignant and malignant tumors. Advancing our knowledge of premalignant immunity and immune changes seen in lesions that develop into invasive cancer versus those that regress offers an exciting opportunity to leverage the immune system for immune prevention and immune interception of premalignancy. Understanding the immune environment of premalignant lesions and how chronic inflammation plays a central role in the evolution of premalignancy is essential for developing effective immunoprevention and immune interceptions. Factors such as host genomics and environmental factors that affect premalignant immunity and the outcome of advanced cancers are equally important in determining the response to immunotherapy. The broad use of antibiotics and factors such as obesity can disrupt a healthy gut microbiome and drive chronic inflammation that suppresses preventive immunity or the antitumor immune response required for successful immunotherapy in advanced cancers. Modifiable lifestyle factors such as diet, obesity, smoking, and stress should be considered in designing immune prevention and interception studies, as well as for patients who receive immunotherapy for advanced cancer treatment. Other factors, such as the overall immune health of patients and existing comorbidities, affect both premalignant immunity and response to immunotherapy and, therefore, should be considered in managing patients with or without cancer. The Society for Immunotherapy of Cancer previously developed an overarching manuscript regarding the challenges and opportunities that exist in cancer immunotherapy, and this manuscript serves as an in-depth follow-up regarding the topics of premalignant immunity, immune interception, and immunoprevention, and the impact of the host on responding to immunotherapy.
BIO25-028: Advancing Clinical Decision-Making: Evaluating AI-Driven Support With Cancer Companion GPT Against Criterion™ Insights
Authors: Jivesh Sharma, Rena J. Vanzo, Neal Sharma, Tawanna St Lewis, Rekha Sharma, Cheryl Reeves, Poonam Sharma, John Tan, Pranav Mukund
Journal: Journal of the National Comprehensive Cancer Network (2025)
BPI25-005: Molecular Biomarker Testing Patterns and Turn-Around Time in US Patients With Advanced Non-Small Cell Lung Cancer
Authors: Xiao Wang, Do Lee, Szu-Chun Yang, Yimeng Li, Pamela R. Soulos, Cary P. Gross, Shi-Yi Wang, Anne C. Chiang
Journal: Journal of the National Comprehensive Cancer Network (2025)
BPI25-010: Increasing Access and Reducing Barriers to Colorectal Cancer Screening (CRCS) Among Low-Income and/or Uninsured Adults Ages 45 to 75 in Texas Through a FIT-First Approach: Project 80%
Authors: Heather M. Johnson, Sonia Gilmore, Diane Benson, Carolyn Bernard, Lewis E. Foxhall
Journal: Journal of the National Comprehensive Cancer Network (2025)

"BPI25-010: Increasing Access and Reducing Barriers to Colorectal Cancer Screening (CRCS) Among Low-Income and/or Uninsured Adults Ages 45 to 75 in Texas Through a FIT-First Approach: Project 80%" published on 28 Mar 2025 by National Comprehensive Cancer Network.
BIO25-024: Real-Time Clinical Trial Data Library in Non-Small Cell Lung (NSCLC), Prostate (PC), and Breast Cancer (BC) to Support Informed Treatment Decisions: Now a Reality With a Fine-Tuned Large Language Model (LLM)
Authors: Rozee Junhan Liu, Anna Forsythe, Jessicca Martin Rege, Peter Kaufman
Journal: Journal of the National Comprehensive Cancer Network (2025)

"BIO25-024: Real-Time Clinical Trial Data Library in Non-Small Cell Lung (NSCLC), Prostate (PC), and Breast Cancer (BC) to Support Informed Treatment Decisions: Now a Reality With a Fine-Tuned Large Language Model (LLM)" published on 28 Mar 2025 by National Comprehensive Cancer Network.
BIO25-026: Innovating a Digital Patient Navigation Platform (DPNP) to Help Patients With Melanoma Access Multidisciplinary Cutaneous Oncology Care
Authors: Govind Warrier, Shannon Kehrli, Renee Ofori, Hao Wang, Daniel Matiaudes, Ivis Alfaro, Naru Sato, James Huang, Cheryl Stratos, Lara Yuan, Adrian Dobs, Rose Wang, Evan Jacob Lipson
Journal: Journal of the National Comprehensive Cancer Network (2025)

"BIO25-026: Innovating a Digital Patient Navigation Platform (DPNP) to Help Patients With Melanoma Access Multidisciplinary Cutaneous Oncology Care" published on 28 Mar 2025 by National Comprehensive Cancer Network.
BPI25-004: Evaluating the Role of Social Determinants of Health (SDoH) in Predicting Surgical Delays and Impact on Healthcare Resources Utilization in Early-Stage NSCLC
Authors: Daniel Young, Tianyuan Hu, Atharv Sharma, Arrvind Sunder, Arindam Paul, Diganta Chowdhury
Journal: Journal of the National Comprehensive Cancer Network (2025)

"BPI25-004: Evaluating the Role of Social Determinants of Health (SDoH) in Predicting Surgical Delays and Impact on Healthcare Resources Utilization in Early-Stage NSCLC" published on 28 Mar 2025 by National Comprehensive Cancer Network.
BIO25-027: Addressing Early Diagnosis Challenges: Utilizing C the Signs Clinical Decision Support Platform for Pancreatic Cancer Risk Assessment
Authors: Sana Raoof, Seema Dadhania, Tushar Patel, Brian Herrick, Bea Bakshi, Miles Payling
Journal: Journal of the National Comprehensive Cancer Network (2025)

"BIO25-027: Addressing Early Diagnosis Challenges: Utilizing C the Signs Clinical Decision Support Platform for Pancreatic Cancer Risk Assessment" published on 28 Mar 2025 by National Comprehensive Cancer Network.
14 years of rotavirus A surveillance: unusual dominance of equine-like G3P[8] genotype with DS-1-like genotype constellation after the pandemic, Belgium, 2009 to 2023
Authors: Mustafa Karataş, Mandy Bloemen, Lize Cuypers, Elke Wollants, Marc Van Ranst, Jelle Matthijnssens
Journal: Eurosurveillance (2025)

IntroductionDespite vaccine availability, rotavirus persists as a leading cause of gastroenteritis in children younger than 5 years.AimWe aimed to evaluate temporal changes in rotavirus epidemiology in Belgium between 2009 and 2023, including the period of the COVID-19 pandemic.MethodsWe collected 8,024 rotavirus-positive stool samples throughout Belgium. For 6,352 samples, we determined the G and/or P genotypes through sequencing of the genes encoding the outer capsid proteins VP7 and VP4.ResultsBefore the COVID-19pandemic, we received on average 622 samples per rotavirus epidemiological year, which decreased to 114 and 111 samples during the two pandemic rotavirus epidemiological years, followed by a peak of 1,048 samples in the first post-pandemic year. Notably, the proportion of cases in the age group 2-5-years increased from 20.3% before to 33% after the pandemic (p < 0.001). Over the 14-year study period, the most common genotypes were G2P[4], G3P[8] and G9P[8]. Post-pandemic data show an unusually strong dominance of the equine-like G3P[8] genotype which carried a DS-1-like genotype constellation in the period 2021 to 2023. Additionally, vaccinated individuals were significantly overrepresented among patients infected with the equine-like VP7 carrying G3P[8] rotavirus compared with other genotypes, including typical human VP7 G3P[8].ConclusionDespite the presence of typical yearly genotype fluctuations, several epidemiological changes were associated with the COVID-19 pandemic, including the unusual dominance of an emerging rotavirus strain against which current vaccines may be less effective. It is essential to closely monitor this strain to determine if the phenomenon is temporary.
Cats as sentinels of mammal exposure to H5Nx avian influenza viruses: a seroprevalence study, France, December 2023 to January 2025
Authors: Pierre Bessière, Jessie Brun, Brandon Hayes, Amélie Marchand, Laura Lebouteiller, Sébastien-Mathieu Soubies, Marie-Christine Cadiergues, Jean-Luc Guérin
Journal: Eurosurveillance (2025)

Circulation of clade 2.3.4.4b highly pathogenic avian influenza H5Nx viruses has intensified in recent years, increasing epizootics and mammalian exposure. Cats, bridging wild and domestic environments, are key for studying cross-species transmission. To assess their exposure in France, we screened 728 outdoor cats (December 2023-January 2025). Seropositivity was 2.6% (19/728), with an estimated seroprevalence at 1.8%. Absence of hunting behaviour was a significant protective factor. These findings highlight high recent exposure and the need for targeted surveillance in cats.
National survey of the rat hepatitis E virus in rodents in Spain, 2022 to 2023
Authors: Javier Caballero-Gómez, Tomás Fajardo-Alonso, Lucía Ríos-Muñoz, Adrián Beato-Benítez, María Casares-Jiménez, Ignacio García-Bocanegra, Raúl Cuadrado-Matías, Alba Martí-Marco, Javier Martínez, Remigio Martínez, Eva Martínez Nevado, Francisco Ruiz-Fons, João Rodrigo Mesquita, Màrius Fuentes, Diana Corona-Mata, Moisés Gonzálvez, Víctor Lizana, Pilar Soriano, Pilar Foronda, Dietmar Crailsheim, Antonio Rivero-Juárez, Antonio Rivero
Journal: Eurosurveillance (2025)

BackgroundRat hepatitis E virus (ratHEV) is an emerging virus causing acute and chronic hepatitis in humans. Rats are the main natural reservoir of this pathogen. Large-scale studies assessing ratHEV circulation in rodents in Spain are lacking.AimWe aimed to determine the prevalence of ratHEV in rats in Spain and evaluate potential transmission risk to humans.MethodsWe designed a cross-sectional nationwide study where black (Rattus rattus) and Norway (R. norvegicus) rats were collected and analysed between 2022 and 2023 for ratHEV infection using real-time (RT)-qPCR testing of liver tissue. Sequencing and analysis of ratHEV shedding in faeces were carried out in positive animals.ResultsRatHEV was detected in 125 of the 481 rats analysed, supposing a prevalence of 26.0% (95 CI%: 22.3-30.1). Positive rats were found in urban (25.6%), and farm (29.8%) settings. Black rats (31.3%) had 1.5 times higher odds of being infected by the virus than Norway rats (22.5%) (p = 0.049). Significantly higher prevalence of ratHEV was detected in rodents sampled from southern (31.9%) than northern (17.8%) Spain (p = 0.003). Viral RNA was detected in faeces from 45.5% of infected rats. Phylogenetic analysis evidenced a wide genetic diversity of ratHEV sequences, some showing high homology with ratHEV strains found in patients from Spain.ConclusionsCirculation of ratHEV appears to be heterogeneous and the virus appears to be endemic among rat populations in Spain, highlighting the possible risk of zoonotic transmission of this emerging virus in this country.
A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4
Authors: Dave Singh, Patricia Guller, Fred Reid, Sarah Doffman, Ulla Seppälä, Ioannis Psallidas, Rachel Moate, Rebecca Smith, Joanna Kiraga, Eulalia Jimenez, Dennis Brooks, Aoife Kelly, Lars H. Nordenmark, Muhammad Waqas Sadiq, Luis Mateos Caballero, Chris Kell, Maria G Belvisi, Hitesh Pandya
Journal: European Respiratory Journal (2025)

Interleukin-33 may have a role in COPD pathobiology. FRONTIER-4 (NCT04631016) investigated tozorakimab (an anti-IL-33 monoclonal antibody) in moderate-to-severe COPD patients with chronic bronchitis receiving dual or triple inhaled therapy. FRONTIER-4 was a phase 2a, randomized, double-blind, placebo-controlled study. Patients received tozorakimab 600 mg or placebo subcutaneously every 4 weeks for 24 weeks. The primary endpoint was change in pre-bronchodilator (BD) FEV1 from baseline to week 12. Secondary outcomes included post-BD FEV1, time-to-first COPDCompEx event and safety. The intent-to-treat population included 135 patients (tozorakimab, n=67; placebo, n=68). At week 12 in the intent-to-treat population, tozorakimab showed a greater increase from baseline in pre-BD FEV1 (least-squares mean [LSM]: 24 mL [80% confidence interval (CI): -15,63]; p=0.216) that was not statistically significant, and in post-BD FEV1 (LSM: 67 mL [80% CI: 17,116]; p=0.044), when compared with placebo. Tozorakimab showed improvements versus placebo (LSM [80% CI]) in change from baseline in pre-BD FEV1 (69 mL [9,130]; p=0.072) and post-BD FEV1 (124 mL [47,201]; p=0.020) at week 12 in a pre-specified subgroup of patients with ≥2 prior exacerbations. Tozorakimab did not significantly reduce the risk of COPDCompEx events (HR: 0.79 [80% CI: 0.57,1.11]; p=0.186) in the intent-to-treat population, although there were greater effects in patients with ≥2 prior exacerbations (hazard ratio: 0.61 [80% CI: 0.37,1.00]). Results were similar in former and current smokers. Tozorakimab was well tolerated. Although the primary endpoint was not met in the intent-to-treat population, tozorakimab showed positive efficacy signals versus placebo in a subgroup of patients with COPD with a high risk of exacerbations.
Enhanced influenza vaccines impact effectiveness in individuals aged 65 years and older, Denmark, 2024/25 influenza season up to 4 March 2025
Authors: Hanne-Dorthe Emborg, Palle Valentiner-Branth, Ramona Trebbien, Amanda Bolt Botnen, Tyra Grove Krause, Bolette Søborg
Journal: Eurosurveillance (2025)

During the 2024/25 influenza season, enhanced and standard-dose influenza vaccines were available for individuals aged 65 and older. Compared with the standard-dose quadrivalent influenza vaccine (QIV), the adjuvanted QIV was significantly more effective, with an overall vaccine effectiveness (VE) of 48% (95% CI: 42-52) vs 33% (95% CI: 24-41) when considering both non-hospitalised and hospitalised patients. The high-dose QIV demonstrated similar effectiveness to the adjuvanted QIV. These findings support the inclusion of enhanced influenza vaccines in future vaccination programmes.
Loss of GalNAc-T14 links O-glycosylation defects to alterations in B cell homing in IgA nephropathy
Authors: Sindhuri Prakash, Nicholas J. Steers, Yifu Li, Elena Sanchez-Rodriguez, Miguel Verbitsky, Isabel Robbins, Jenna Simpson, Sharvari Pathak, Milan Raska, Colin Reily, Anna Ng, Judy Liang, Natalia DeMaria, Amanda Katiraei, Kelsey O'Stevens, Clara Fischman, Samantha Shapiro, Swetha Kodali, Jason McCutchan, Heekuk Park, Djamila Eliby, Marco Delsante, Landino Allegri, Enrico Fiaccadori, Monica Bodria, Maddalena Marasa, Elizabeth Raveche, Bruce A. Julian, Anne-Catrin Uhlemann, Krzysztof Kiryluk, Hong Zhang, Vivette D. D'Agati, Simone Sanna-Cherchi, Jan Novak, Ali G. Gharavi
Journal: Journal of Clinical Investigation (2025)

Aberrant O-glycosylation of the IgA1 hinge region is a characteristic finding in patients with IgA nephropathy (IgAN) and is thought to contribute to immune-complex formation and kidney injury. Other studies have suggested that abnormalities in mucosal immunity and lymphocyte homing are major contributors to disease. We identified a family with IgAN segregating a heterozygous predicted loss-of-function (LOF) variant in GALNT14, the gene encoding N-acetylgalactosaminyltransferase 14, one of the enzymes involved in mucin-type protein O-glycosylation. While GALNT14 is expressed in IgA1-producing cells, carriers of the LOF variant did not have altered levels of poorly glycosylated IgA1, suggesting other disease mechanisms. Investigation of Galnt14 null mice revealed elevated serum IgA levels and ex vivo IgA production by B cells. These mice developed glomerular IgA deposition with aging and after induction of sterile colitis. Galnt14 null mice also displayed an attenuated mucin layer in the colon and redistribution of IgA-producing cells from mucosal to systemic sites. Adoptive-transfer experiments indicated impaired homing of spleen-derived Galnt14 deficient B lymphocytes, resulting in increased retention in peripheral blood. These findings suggest that abnormalities in O-glycosylation alter mucosal immunity and B lymphocyte homing, pointing to an expanded role of aberrant O-glycosylation in the pathogenesis of IgAN.
Effect of video conferencing between primary and secondary care specialists on type 2 diabetes medication
Authors: Thim Prætorius, Anne Sofie Baymler Lundberg, Eskild Klausen Fredslund, Niklas Blach Rossen, Søren Gregersen, Anders Prior, Esben Søndergaard, Søren Tang Knudsen, Annelli Sandbæk
Journal: npj Digital Medicine (2025)

Although promising, the clinical impact of video conferencing between primary and secondary care specialists lacks trial evidence. We conducted a two-arm RCT (clinicaltrials.gov: NCT05268081) to evaluate whether four video conferences over 12 months between endocrinologists and general practitioners improved medication for people with type 2 diabetes (T2D). Twenty-seven of 100 general practices in Aarhus, Denmark were matched and randomized. Primary outcomes: the proportion of people with T2D and 1) ischemic heart disease treated with glucagon-like peptide 1 receptor agonist (GLP1-RA) and/or sodium glucose cotransporter 2 inhibitor (SGLT2I), 2) micro/macro-albuminuria treated with angiotensin-converting-enzyme-inhibitor (ACE) or angiotensin-2-receptorantagonist (AT2), 3) low-density lipoprotein >2.5 mmol/L treated with statins. Results showed a 17.6% difference [95% CI 4.6%; 30.7%] in GLP1-RA/SGLT2I prescriptions and minimal differences for ACE/AT2 (−1.1% [95% CI −2.8%; 0.6%]) and statins (0.0% [95% CI −3.5%; 3.6%]), attributed to a ceiling effect. Video conferencing can help bridge treatment gaps, particularly for recently updated guidelines.
The Relationship of the Microbiome, Associated Metabolites and the Gut Barrier with Pancreatic Cancer
Authors: Neil Daniel, Riccardo Farinella, Flavia Belluomini, Almir Fajkic, Cosmeri Rizzato, Pavel Souček, Daniele Campa, David J Hughes
Journal: Seminars in Cancer Biology (2025)

Pancreatic cancers have high mortality and rising incidence rates which may be related to unhealthy western-type dietary and lifestyle patterns as well as increasing body weights and obesity rates. Recent data also suggest a role for the gut microbiome in the development of pancreatic cancer. Here, we review the experimental and observational evidence for the roles of the oral, gut and intratumoural microbiomes, impaired gut barrier function and exposure to inflammatory compounds as well as metabolic dysfunction as contributors to pancreatic disease with a focus on pancreatic ductal adenocarcinoma initiation and progression. We also highlight some emerging gut microbiome editing techniques currently being investigated in the context of pancreatic disease. Notably, while the gut microbiome is significantly altered in PDAC and its precursor diseases, its utility as a diagnostic and prognostic tool is hindered by a lack of reproducibility and the potential for reverse causality in case-control cohorts. Future research should emphasise longitudinal and mechanistic studies as well as integrating lifestyle exposure and multi-omics data to unravel complex host-microbiome interactions. This will allow for deeper aetiologic and mechanistic insights that can inform treatments and guide public health recommendations.
Leveraging electronic medical records to evaluate a computerized decision support system for staphylococcus bacteremia
Authors: Julia Palm, Ssuhir Alaid, Danny Ammon, Julian Brandes, Andreas Dürschmid, Claudia Fischer, Jonas Fortmann, Kristin Friebel, Sarah Geihs, Anne-Kathrin Hartig, Donghui He, Andrew J Heidel, Petra Hetfeld, Roland Ihle, Suzanne Kahle, Verena Koi, Margarethe Konik, Frauke Kretzschmann, Henner Kruse, Norman Lippmann, Christoph Lübbert, Gernot Marx, Rafael Mikolajczyk, Anne Mlocek, Stefan Moritz, Christoph Müller, Susanne Müller, Ariadna Pérez Garriga, Lo An Phan-Vogtmann, Diana Pietzner, Mathias W Pletz, Mario Popp, Maike Rebenstorff, Jonas Renz, Florian Rißner, Rainer Röhrig, Kutaiba Saleh, Sebastian G Schönherr, Cord Spreckelsen, Anja Stempel, Abel Stolz, Eric Thomas, Susanne Thon, Daniel Tiller, Sebastian Uschmann, Sebastian Wendt, Thomas Wendt, Philipp Winnekens, Oliver Witzke, Stefan Hagel, André Scherag
Journal: npj Digital Medicine (2025)
Comparison of safety and efficacy of negative pressure aspiration assisted retrograde intrarenal surgery and traditional percutaneous nephrolithotomy in the treatment of upper urinary tract stones larger than 2cm: a systematic review and meta-analysis
Authors: Zhaoxin Ying, Shaoxiong Ming, Rui Yang, Bangyu Zou, Yiying Jia, Meng Shu, Ziyu Fang, Xiaofeng Gao
Journal: International Journal of Surgery (2025)